Revimmune
2006
FOUNDED
M&A
STATUS
1-10
EMPLOYEES
M&A
LATEST DEAL TYPE
3
FINANCING ROUNDS
Description
Developer of therapies for autoimmune diseases. The Company's lead antineoplastic technology employs a bioengineered poliovirus construct and targets cancerous central nervous cells with great specificity recombinant poliovirus therapy has the potential to significantly reduce or eliminate current chemotherapy side-effects while completely destroying abnormal cancerous tissue.
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Biotechnology
Other Industries
Discovery Tools (Healthcare)
Acquirer
Accentia Biopharmaceuticals
Primary Office
- 324 South Hyde Park Avenue
- Suite 350
- Tampa, FL 33606
- United States
Revimmune Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Revimmune‘s full profile, request access.
Request full access to PitchBookRevimmune Former Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Revimmune‘s full profile, request access.
Request full access to PitchBook